Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentary

LADA: Time for a New Definition

  1. Maria J. Redondo⇓
  1. Diabetes and Endocrinology Section, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas
  1. Corresponding author: Maria J. Redondo, redondo{at}bcm.edu.
Diabetes 2013 Feb; 62(2): 339-340. https://doi.org/10.2337/db12-1171
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

In this issue of Diabetes, Zhou et al. (1) report on the prevalence and characteristics of latent autoimmune diabetes in adults (LADA) in China. Findings from this study underscore the profound need for a new definition of LADA.

LADA, a slowly progressive form of autoimmune diabetes that develops in adults and does not require insulin therapy for some time after diagnosis, was first described over 25 years ago (2). Subsequently, clinical, metabolic, immunological, and genetic characteristics that are unique to LADA have been identified (3–6). For example, relative to patients with type 1 diabetes (T1D), those with LADA are more likely to be obese and have other elements of the metabolic syndrome. They are also more likely to retain greater β-cell function, express a single autoantibody (particularly GAD65) and certain GAD65 epitopes (7), and carry the transcription factor 7-like 2 (TCF7L2) gene polymorphism, which is strongly associated with type 2 diabetes (T2D) (8). However, the rationale for the strict criteria that are most often used to define LADA, including age >30 years at diagnosis and insulin independence for at least 6 months after diagnosis (5), have been questioned repeatedly (9–13). Furthermore, there is substantial heterogeneity in LADA, with some cases closely resembling T1D (e.g., low BMI, association with other autoimmune diseases), and others that share many features with T2D (14–16). Many authors and clinicians question the evidence base for defining LADA as a distinct entity and propose instead that LADA and childhood-onset T1D are opposing ends of the same continuum of autoimmune diabetes.

The multicenter study by Zhou et al. evaluated 4,880 subjects in China with diabetes diagnosed at age >30 years, enrolled within 1 year of diagnosis, and who did not develop diabetic ketoacidosis or insulin dependence for at least 6 months after diagnosis. LADA was diagnosed in 5.9% of these patients based on GAD65 autoantibody positivity, and the rest were classified as T2D. In the south of China, compared with the north, LADA was more prevalent and was characterized by higher GAD65 titers and lower frequency of both metabolic syndrome and obesity. Relative to LADA patients with low GAD65 titers, those with high GAD65 titers were younger, had lower BMI, lower β-cell function, and higher frequency of T1D-associated HLA haplotypes. Thus, consistent with previous studies (14,15), LADA with high GAD65 titers resembled T1D in the current report.

The authors are to be commended for accomplishing a 100% rate of GAD65 autoantibody testing, 6-month assessment visit, and GAD65 autoantibody assay reproducibility in their remarkably large study. Comparisons of characteristics between Chinese LADA patients and those in other countries are difficult to interpret because of differences in methods of ascertainment, subject selection, and laboratory techniques. Nonetheless, an intriguing implication of the study is that, while the frequency of childhood and adult onset T1D is similar in countries with high incidence of T1D (17), in China, where the incidence is low, LADA may be the most common form of autoimmune diabetes. However, this interpretation requires confirmation of the autoimmune nature of the cases identified as LADA, which may be challenging, as we will discuss.

This study highlights two critical issues in the current definition of LADA (5). One of them is reflected by the authors’ observation that patients with LADA and low GAD65 titers were not different from T2D patients in sex, age at diagnosis, HbA1c, β-cell function reserve, or components of the metabolic syndrome. On the other hand, all of those features were different in LADA with high GAD65 titers and T2D (1). One possible interpretation is that the pathogenesis of diabetes with low GAD65 titers is not truly different from that of T2D. Single autoantibody expression, particularly low titers, lacks predictive value for progression to T1D (18). GAD65 autoantibodies are particularly prone to this “biological false positivity” (G. Eisenbarth, personal communication), and their expression in healthy subjects has been reported more frequently than other autoantibodies (19). In the study by Zhou et al. (as in any other study on autoimmune diabetes), analysis of additional anti-islet autoantibodies would have been of interest. It is likely that higher number of positive autoantibodies would have correlated with higher titers of GAD65 autoantibodies. Therefore, single autoantibody positivity at low titers may not be sufficient evidence that β-cell autoimmunity plays a significant role in the pathogenesis of diabetes, and, thus, it may not appropriately classify diabetes as autoimmune, be it LADA or childhood onset.

A second key issue is the failure of the existing LADA criteria to capture a pathogenic mechanism requiring specific preventive and therapeutic approaches. Both criteria of diagnosis in adulthood and transient insulin independence attempt to reflect slowly progressing β-cell loss. However, it is insulin resistance, which does not significantly contribute to most cases of autoimmune T1D, that plays a unique pathogenic role in slow-onset autoimmune diabetes. Furthermore, the risk of metabolic syndrome and cardiovascular complications in patients with insulin resistance turns the latter into an essential therapeutic target. Diabetes results from insulin production not meeting the demands posed by insulin resistance. In patients with protracted autoimmune destruction of β-cells, clinical diabetes may manifest itself when insulin resistance renders insufficient their dwindled insulin secretion capacity (Fig. 1). This hypothesis is supported by observations that β-cell function is greater in LADA than in T1D patients, as well as in obese relative to lean children at the onset of T1D (20). Defining a distinct entity with a double component of β-cell autoimmunity and insulin resistance would facilitate identification of patients—children or adults—who may benefit from addressing both aspects of their diabetes.

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

Model of progression to diabetes determined by insulin secretion and insulin resistance. Clinical diabetes manifests when anti-islet autoimmunity (in T1D) or nonautoimmune β-cell dysfunction (in T2D) decrease insulin secretory capacity below a threshold determined by insulin resistance, which can vary from low (in T1D) to high (in T2D). Although not illustrated in this figure, variation in the rate of insulin secretion decrease also determines time to progression to diabetes. In LADA, as opposed to T1D and T2D, three mechanisms, namely, anti-islet autoimmunity, nonautoimmune β-cell dysfunction, and elevated insulin resistance, likely contribute to disease.

In summary, the definition of LADA is unsatisfactory in many respects, some of which are highlighted in the study by Zhou et al. Cases without biologically significant β-cell autoimmunity can be classified as LADA. The present diagnostic criteria do identify some patients with slowly progressive β-cell destruction but leave out many more, including young adults and adolescents. Furthermore, the current description of LADA fails to capture insulin resistance, a unique pathogenic mechanism and a therapeutic target in this form of autoimmune diabetes. It is time for a new definition of LADA.

ACKNOWLEDGMENTS

No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying original article, p. 543.

  • © 2013 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

REFERENCES

  1. ↵
    1. Zhou Z,
    2. Xiang Y,
    3. Ji L,
    4. et al.,
    5. on behalf of the LADA China Study Group
    . Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China Study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 2013;62:543–550
  2. ↵
    1. Groop LC,
    2. Bottazzo GF,
    3. Doniach D
    . Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986;35:237–241pmid:3510930
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Tuomi T,
    2. Groop LC,
    3. Zimmet PZ,
    4. Rowley MJ,
    5. Knowles W,
    6. Mackay IR
    . Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993;42:359–362pmid:8425674
    OpenUrlAbstract/FREE Full Text
    1. Pozzilli P,
    2. Di Mario U
    . Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001;24:1460–1467pmid:11473087
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Fourlanos S,
    2. Dotta F,
    3. Greenbaum CJ,
    4. et al
    . Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005;48:2206–2212pmid:16193284
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Naik RG,
    2. Brooks-Worrell BM,
    3. Palmer JP
    . Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009;94:4635–4644pmid:19837918
    OpenUrlCrossRefPubMed
  6. ↵
    1. Maruyama T,
    2. Oak S,
    3. Shimada A,
    4. Hampe CS
    . GAD65 autoantibody responses in Japanese latent autoimmune diabetes in adult patients. Diabetes Care 2008;31:1602–1607pmid:18487477
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Cervin C,
    2. Lyssenko V,
    3. Bakhtadze E,
    4. et al
    . Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008;57:1433–1437pmid:18310307
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Rolandsson O,
    2. Palmer JP
    . Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia 2010;53:1250–1253pmid:20336277
    OpenUrlCrossRefPubMedWeb of Science
    1. Palmer JP,
    2. Hampe CS,
    3. Chiu H,
    4. Goel A,
    5. Brooks-Worrell BM
    . Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005;54(Suppl. 2):S62–S67pmid:16306342
    OpenUrlAbstract/FREE Full Text
    1. Gale EA
    . Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005;48:2195–2199pmid:16193287
    OpenUrlCrossRefPubMed
    1. Djekic K,
    2. Mouzeyan A,
    3. Ipp E
    . Latent autoimmune diabetes of adults is phenotypically similar to type 1 diabetes in a minority population. J Clin Endocrinol Metab 2012;97:E409–E413pmid:22205710
    OpenUrlCrossRefPubMed
  9. ↵
    1. Leslie RD,
    2. Kolb H,
    3. Schloot NC,
    4. et al
    . Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev 2008;24:511–519pmid:18615859
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Lohmann T,
    2. Kellner K,
    3. Verlohren HJ,
    4. et al
    . Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 2001;44:1005–1010pmid:11484077
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Pettersen E,
    2. Skorpen F,
    3. Kvaløy K,
    4. Midthjell K,
    5. Grill V
    . Genetic heterogeneity in latent autoimmune diabetes is linked to various degrees of autoimmune activity: results from the Nord-Trøndelag Health Study. Diabetes 2010;59:302–310pmid:19833889
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Zampetti S,
    2. Capizzi M,
    3. Spoletini M,
    4. et al.,
    5. for the NIRAD Study Group
    . GADA Titer-Related Risk for Organ-Specific Autoimmunity in LADA Subjects Subdivided according to Gender (NIRAD Study 6). J Clin Endocrinol Metab 2012; 97:3759–3765pmid:22865904
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Thunander M, Petersson C, Jonzon K, et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract 2008;82:247–255
  14. ↵
    1. Yu L,
    2. Miao D,
    3. Scrimgeour L,
    4. Johnson K,
    5. Rewers M,
    6. Eisenbarth GS
    . Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 2012;61:179–186pmid:22124462
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Seyfert-Margolis V,
    2. Gisler TD,
    3. Asare AL,
    4. et al
    . Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006;55:2588–2594pmid:16936208
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Redondo MJ,
    2. Rodriguez LM,
    3. Escalante M,
    4. O’Brian Smith E,
    5. Balasubramanyam A,
    6. Haymond MW
    . Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes. Pediatr Diabetes 2012; 13:564–571pmid:22642603
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes: 62 (2)

In this Issue

February 2013, 62(2)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
LADA: Time for a New Definition
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
LADA: Time for a New Definition
Maria J. Redondo
Diabetes Feb 2013, 62 (2) 339-340; DOI: 10.2337/db12-1171

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

LADA: Time for a New Definition
Maria J. Redondo
Diabetes Feb 2013, 62 (2) 339-340; DOI: 10.2337/db12-1171
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Lifting the Veil on the “Phosphate Flush,” a Cryptic Phenomenon of Experimental Pancreatic Islet Physiology
  • Window of Opportunity: Targeting ANGPTL4 Improves Triglyceride Levels in Maternal Obesity During Pregnancy
  • New Antidiabetes Agent Targeting Both Mitochondrial Uncoupling and Pyruvate Catabolism: Two Birds With One Stone
Show more Commentary

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.